GlassScriptPhysician profile
Paul E Oberstein
NPI 1265686075
$223,203.92
in general payments reported to CMS, 2019-2025
29 companies · $64K in 2025
The $64K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $3,761 · 2021: $23K · 2022: $36K · 2023: $4,572 · 2024: $73K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Consulting Fee: $15K · Travel and Lodging: $12K · Honoraria: $4,350 · Food and Beverage: $3,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,600.00 |
| Consulting Fee | $14,555.00 |
| Travel and Lodging | $12,186.52 |
| Honoraria | $4,350.00 |
| Food and Beverage | $3,155.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $96,191.21 | 2024-2025 | Onivyde, Tazverik, Somatuline Depot |
| Jazz Pharmaceuticals INC. | $32,812.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $22,909.08 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $22,892.68 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $15,632.49 | 2019-2021 | |
| Daiichi Sankyo INC. | $9,662.54 | 2021 | |
| Abbvie INC. | $5,633.80 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $4,359.55 | 2024-2025 | Rybrevant |
| Biocompatibles Uk LTD | $3,533.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,740.00 | 2024 | |
| Eli Lilly and Company | $1,700.00 | 2024 | |
| Eisai INC. | $1,700.00 | 2022 | |
| Genentech USA, INC. | $1,650.00 | 2020 | |
| Ipsen Bioscience INC. | $1,393.94 | 2019 | |
| Hoffmann-La Roche Limited | $985.69 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $241.96 | 2025 | |
| Tempus Ai, INC | $105.61 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $44.64 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.10 | 2024 | Opdivo |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Oberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.